Seeking Alpha

ViroPharma (VPHM +3.4%) trades higher after releasing its 2013 outlook this morning. The company...

ViroPharma (VPHM +3.4%) trades higher after releasing its 2013 outlook this morning. The company says it expects net product sales to be between $450M to $475M. Analysts are looking for around $467M. The numbers are encouraging, because Cinryze has become key to the drug developer's future as the it's former blockbuster antibiotic Vancocin is expected to see sales hurt by the potential entry of generic rivals going forward.
From other sites
Comments (1)
  • cgm
    , contributor
    Comments (155) | Send Message
     
    The management here has played their drug development well. They have gone from a "one-trick pony" to a firm that brings additional income sources to market in thime to more than offset the effects of generic competition. The stock has acted well as a result. One very pleased stockholder here.
    7 Jan 2013, 01:04 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs